Clinical Trials Logo

Clinical Trial Summary

Cystic fibrosis (CF) is the most common hereditary life-threatening condition in Belgium. Because of a dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) channel, chloride is unable to move to the cell surface and mucus becomes more viscous. Consequently, CF patients are not able to clear their lungs efficiently, and trapped bacteria can lead to chronic infection and inflammation of the lungs, and ultimately respiratory failure. CF lung disease starts at birth due to muco-inflammatory processes and is associated with a significantly altered microbial colonization of the infant airways compared to infants without CF. Additionally, young children with CF suffer from viral infections as often as their healthy peers, but the episodes are more severe and often prolonged. Moreover, frequent viral infections in children with CF contribute towards a more pathogenic airway microbiome at a young age. Although this link has been previously reported, the exact mechanisms by which this occurs need to be elucidated. A pulmonary exacerbation in CF is characterized by an increase in respiratory symptoms, general symptoms and a decline in lung function. Most young children with CF suffer from a mean of 4 exacerbations per year for which antibiotics are prescribed. Despite the current novel therapies in CF, treatment of respiratory infections stay relevant and is a greater challenge with increasing survival. The key objective of this study is to gain insights into the mechanisms by which viral infections leading to pulmonary exacerbations induce a more pathogenic microbiome in young children with CF. About forty participants will be recruited at the paediatric CF clinic of the Antwerp University Hospital. Inclusion criteria are an age of less than 5 years and a diagnosis of CF. There are no exclusion criteria. Duration of the study is 1 year to cover for seasonality of clinical symptoms. Study visits are scheduled at 3-month intervals corresponding with the regular follow up, or unscheduled during an acute pulmonary exacerbation. From all participants, two oropharyngeal swabs (for microbiome analysis and for immunological/mucin analysis) will be collected at set time points. For the linking of the laboratory data to the clinical characteristics, we will examine demographics, environmental exposures, and disease markers of CF. Next to the collection of the oropharyngeal swabs, a history, physical examination, and technical investigations will be performed at the study visits.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06188988
Study type Observational [Patient Registry]
Source University Hospital, Antwerp
Contact
Status Enrolling by invitation
Phase
Start date November 1, 2023
Completion date October 31, 2025

See also
  Status Clinical Trial Phase
Terminated NCT04898023 - Zinc and Green Tea Extract for Community Respiratory Viral Infections Phase 2
Withdrawn NCT04842331 - PREvent Viral Exposure and Transmission Study: a COVID-19 (SARS-CoV-2) PEP Study (PREVENT) Phase 2/Phase 3
Completed NCT02260596 - Respiratory Viral Infections in Pediatric Transplantation N/A
Not yet recruiting NCT06099873 - A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents Phase 3
Completed NCT04898140 - The Evaluation of Cellular and Humoral Immunity to COVID-19 in Moscow Residents
Completed NCT04611061 - Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
Not yet recruiting NCT05618483 - Xylitol Based Nasal Spray for COVID-19 Treatment N/A
Recruiting NCT06149494 - RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection Phase 2
Terminated NCT04141917 - Test-and-treat for Influenza in Homeless Shelters Phase 4
Recruiting NCT06017310 - Respiferon Project
Completed NCT04141930 - Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle Phase 4
Completed NCT05846360 - The Technical and Operational Performance of the QuidelOrtho Savanna RVP4 Analyzer
Completed NCT04532411 - COVID-19 Testing Sample Acquisition Throughput and Efficiency
Active, not recruiting NCT04258059 - Wells and Enteric Disease Transmission Trial (WET - Trial) N/A
Active, not recruiting NCT04482673 - Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection Phase 4
Not yet recruiting NCT05946538 - Clinical Evaluation of SARS-COV-2 (COVID-19), Influenza and RSV 8-Well MT-PCR Panel for In Vitro Diagnostics N/A
Recruiting NCT05092607 - Evaluation of the Detection Performance of the N Antigenemia of SARS-CoV-2 in the General Population for the Diagnosis and Screening of COVID-19 N/A
Recruiting NCT05913700 - Effect of Respiratory Virus Infection on EmeRgencY Admission Study (EVERY Study)
Recruiting NCT04826991 - Wells and Enteric Disease Transmission N/A
Terminated NCT04664075 - Predicting Severity and Disease Progression in Influenza-like Illness (Including COVID-19)